I just looked it up as I recall that ACADIA did consumed that one time right to go for ROW on exclusive basis...
https://www.neurenpharma.com/pdf/2584cbc8-7947-47a9-be15-4771943472fd/Neuren-retains-exNorth-America-appoints-investment-bank.pdf
"Neuren (NEU) - ASX Announcement 1 February 2019
Neuren retains trofinetide ex-North America rights and appoints investment bank
Melbourne, Australia, 1 February 2019: Neuren Pharmaceuticals (ASX: NEU) today reported that the
period of exclusive negotiation with ACADIA Pharmaceuticals for the rights to develop and
commercialize trofinetide for territories outside North America concluded on 31 January 2019.
The licence agreement with ACADIA for North America provided ACADIA with a first right of negotiation
prior to Neuren negotiating with other parties. Having considered the terms of a proposal received from
ACADIA, the Neuren Board has determined it would not be in the best interests of Neuren’s
shareholders to accept the offer.
Anticipating discussions with third parties in the US, Europe and Japan, Neuren has now appointed
Torreya, a global investment bank specialising in life sciences, as its corporate advisor. Torreya will work
closely with Neuren management and assist the board in considering all potential corporate transactions
including individual products, territories, or Neuren’s entire business.
The Neuren and ACADIA teams are collaborating very effectively on the development of trofinetide for
North America, including the ongoing preparations for the Rett syndrome Phase 3 trial, which remains
on-track to commence in the second half of 2019.
Neuren’s Executive Chairman Richard Treagus commented: “ACADIA is proving to be a very capable and
committed partner in the US and Neuren places tremendous value on this partnership. At the same
time as important progress is being made in the US, we recognise our shareholders’ expectations and
are taking appropriate steps towards securing maximum market value recognition for Neuren’s
neurology assets, trofinetide and NNZ-2591 worldwide.”"
Ann: Trofinetide ex-North America exclusive negotiation period, page-79
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.92 |
Change
0.310(2.28%) |
Mkt cap ! $1.784B | |||
| Open | High | Low | Value | Volume |
| $13.60 | $14.00 | $13.51 | $2.360M | 170.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 14 | 560 | $13.91 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.93 | 141 | 3 |
View Market Depth
| Last trade - 14.28pm 13/09/2024 (20 minute delay) ? |
| NEU (ASX) Chart |